TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01940939

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
Study: NCT02589275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL Tablet 2.8 mg
Description: TNX-102 SL 2.8 mg tablet taken daily at bedtime
Study: NCT01042366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Study: NCT01972022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EES SYNERGY™
Description: percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZES, RESOLUTE Integrity™
Description: percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
Study: NCT04325074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice
Description: During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice + skill training
Description: In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
Study: NCT00965653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: \>/= 5 mg po weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: \>/= 5 mg po weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 7.5 - 25 mg weekly (oral or parenteral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 7.5 - 25 mg weekly (oral or parenteral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg sc weekly (QW)for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg sc every other week (Q2W) for 12 weeks
Study: NCT02188797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group MI risk reduction program
Study: NCT03665103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser-assisted ICSI
Description: Laser opening of the zona pellucida.
Study: NCT02895529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters \[mL\]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
Study: NCT02551289

Intervention type: OTHER
Intervention: Gluten free diet
Description: Patients will follow a gluten free diet
Study: NCT03467568

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: 300mg sodium chloride will be provided in a capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: 300mg sodium chloride will be provided in a capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule
Description: A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Twice during the morning a drink of 150ml of water will be consumed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Twice during the morning a drink of 150ml of water will be consumed

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: No water consumed
Description: No water will be consumed during the monring

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: No water consumed
Description: No water will be consumed during the monring
Study: NCT02386033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (ATV)
Description: After SRP, ATV gel was delivered subgingivally into the pocket

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study: NCT04102293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual K-files
Description: manual instrumentation used in pulp therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual K-files
Description: manual instrumentation used in pulp therapy
Study: NCT00249873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel (SR25990C)
Description: oral administration (tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration (tablets)
Study: NCT01756989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide, etoposide, celecoxib
Description: Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day.
Study: NCT04521556

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia with light general anesthesia
Description: Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ml and fentanyl 8.3 μg/ml.~Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative epidural analgesia
Description: Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1.~Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous intravenous analgesia
Description: Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
Study: NCT03865030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: audiovestibular function
Description: Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: audiovestibular function
Description: Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness.
Study: NCT00692575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving, education based telephone counseling
Description: Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Intervention
Description: The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
Study: NCT01518803

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean-style breakfast
Description: The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western-style breakfast
Description: The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
Study: NCT04121338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Celiac ganglion block
Description: The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
Study: NCT05882500

Intervention type: OTHER
Intervention: No intervention, observation
Study: NCT02016443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
Study: NCT02783612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucose buddy application
Study: NCT02718872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco cessation online training
Description: The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules.
Study: NCT03920475

Intervention type: DRUG
Intervention: Sertraline or venlafaxine
Description: Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immune parameters
Description: Serum was taken before, during an after treatment for measurement of different immune parameters.
Study: NCT01348139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Inhaled via single inhaler device (SID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Inhaled via single inhaler device (SID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Inhaled via single inhaler device (SID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Inhaled via Turbuhaler inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3199
Description: Inhaled via Turbuhaler inhaler

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AZD3199 Placebo
Description: Inhaled via Turbuhaler inhaler and SID
Study: NCT01164202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: placebo 3cps/days 4 weeks over 6 during 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 3cps/days 4 weeks over 6 during 1 year

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: transarterial chemoembolization
Description: Chimioembolisation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization
Description: Chimioembolisation
Study: NCT00165503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALIMTA
Study: NCT01251042

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sangvia
Description: The Sangvia® Blood Salvage System used to collect blood intra-operatively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sangvia
Description: The Sangvia® Blood Salvage System used to collect blood intra-operatively.
Study: NCT00145886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH
Description: Subjects will be treated with rhPTH for 12 months.
Study: NCT01304797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302 Monotherapy
Description: Escalating doses of MM-302 as a single agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302 in combination with trastuzumab
Description: Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302 in combination with trastuzumab q3w
Description: Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-302 in combination with trastuzumab and cyclophosphamide
Description: Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
Study: NCT02317887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RS1 AAV Vector
Description: Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RS1 AAV Vector
Description: Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
Study: NCT01278342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: 40 mg intramuscular (i.m.) every 28 days for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: 40 mg intramuscular (i.m.) every 28 days for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandostatin LAR
Description: 40 mg intramuscular (i.m.) every 28 days for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegvisomant
Description: Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
Study: NCT02317887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RS1 AAV Vector
Description: Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RS1 AAV Vector
Description: Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RS1 AAV Vector
Description: Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RS1 AAV Vector
Description: Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
Study: NCT02700854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% carbon-dioxide inhalation
Description: 5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE \> -5 mmol/L in arterial blood gas samples
Study: NCT01278342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline
Description: Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~1. st week: 0.25 mg twice a week (0.50 mg/week)~2. nd week: 0.50 mg/week twice a week (1 mg/week)~3. rd week: 0.50 mg four times a week (2 mg/week)~4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)
Study: NCT02016768

Intervention type: PROCEDURE
Intervention: decompressive cervical surgery
Description: To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
Study: NCT05102318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Pulp Capping
Description: Direct Pulp Capping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Pulp Capping
Description: Direct Pulp Capping

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy
Description: Partial Pulpotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy
Description: Partial Pulpotomy
Study: NCT04478058

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live CBT
Description: Weekly in-person Cognitive Behavioural Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-CBT
Description: Weekly online Cognitive Behavioural Therapy
Study: NCT04110431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing
Description: Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold\<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Implantation of a LV pacing lead is attempted using the standard-of-care technique first.